Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. Transactions on Cancer
  4. Vol 4, Issue 1, 2023

Effect evaluation of transcatheter arterial chemoembossment combined with PD1 inhibitor in the treatment of advanced liver cancer

Download as PDF

DOI: 10.23977/tranc.2023.040120 | Downloads: 14 | Views: 233

Author(s)

Yuanlong Zhou 1, Yuan Wang 1, Linwei Kang 1, Zan Li 1, Hao Lu 1

Affiliation(s)

1 Department of Hepatobiliary Surgery, Affiliated Hospital of Hebei University, Baoding, 071000, China

Corresponding Author

Hao Lu

ABSTRACT

Advanced liver cancer is a malignant tumor with rapid progress and poor prognosis, and the effectiveness of traditional treatment methods is limited. The purpose of this study is to evaluate the therapeutic effect of transcatheter arterial chemoembossmen (TACE) combined with PD1 inhibitor in patients with advanced liver cancer. A cohort of patients diagnosed with advanced liver cancer was randomly assigned to either the Combined Treatment Group (CTG) or the Single Treatment Group (STG). The CTG underwent treatment involving TACE in combination with a PD-1 inhibitor, while the STG received conventional therapy. The therapeutic effects of both groups were comprehensively assessed through survival analysis, adverse reaction analysis, and evaluations of quality of life. The CTG exhibited significant advantages in terms of survival rate, with the survival curve indicating a more favorable trend (p < 0.05). Adverse reaction analysis revealed that the incidence of adverse reactions in the CTG was slightly higher than that in the STG, but the difference was statistically significant (p < 0.05). Quality of life assessments indicated superior overall quality of life and physiological function in the CTG, although there was a slight decrement in symptoms compared to the STG. In conclusion, the combined therapy of TACE and PD-1 inhibitor demonstrated notable efficacy in treating advanced liver cancer, leading to a significant improvement in both the survival rate and overall quality of life for patients. Despite the presence of some adverse reactions, the therapeutic advantages of this combination warrant careful consideration. In clinical practice, doctors need to weigh the advantages and disadvantages of combined treatment according to the individual differences and treatment expectations of patients. Future research should further verify the long-term efficacy of this treatment scheme and confirm its position in the treatment of advanced liver cancer through larger-scale clinical trials.

KEYWORDS

Transcatheter arterial chemoembossment; PD1 inhibitor; Effect evaluation; advanced liver cancer

CITE THIS PAPER

Yuanlong Zhou, Yuan Wang, Linwei Kang, Zan Li, Hao Lu, Effect evaluation of transcatheter arterial chemoembossment combined with PD1 inhibitor in the treatment of advanced liver cancer. Transactions on Cancer (2023) Vol. 4: 139-146. DOI: http://dx.doi.org/10.23977/tranc.2023.040120.

REFERENCES

[1] Shao, G. L., Zheng, J. P., Guo, L. W., Chen, Y. T., Zeng, H., & Yao, Z.. (2017). Evaluation of efficacy of transcatheter arterial chemoembolization combined with computed tomography-guided radiofrequency ablation for hepatocellular carcinoma using magnetic resonance diffusion weighted imaging and computed tomography perfusion imaging:. Medicine, 96(3), 5518.
[2] Liu, W., Xiu, N., Zhao, J., & Zhao, L. (2020). Enhanced therapeutic effect of transcatheter arterial chemoembolization combined with radioactive i-125 seed implantation on liver cancer. Oncology letters, 20(3), 2493-2498.
[3] Su, D. (2021). The transcatheter arterial chemoembolization combined with targeted nanoparticle delivering sorafenib system for the treatment of microvascular invasion of hepatocellular carcinoma. Bioengineered, 12(2), 11124-11135.
[4] You, R., Yin, G., Xu, H., Zhu, X., Zhang, Q., & Wang, Q., et al. (2021). Camrelizumab in combination with tace for the treatment of unresectable hepatocellular carcinoma (hcc): a multicenter, single-arm, prospective real-world study. Journal of Clinical Oncology, 39(15l), 16114.
[5] Wang, F., Li, N., Hou, R., Wang, L., & Lu, J. (2020). Treatment of parkinson's disease using focused ultrasound with gdnf retrovirus-loaded microbubbles to open the blood–brain barrier. Open Chemistry, 18(1), 882-889.
[6] Xu, X., & Meng, Q. (2018). Drug effect analysis of sorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma. Pakistan journal of pharmaceutical sciences, 31(4), 1751-1755.
[7] Jiang, Y., Zhou, S., Shen, G., Jiang, H., & Zhang, J. (2018). Microwave ablation combined with transcatheter arterial chemoembolization is effective for treating unresectable hepatoblastoma in infants and children. Medicine, 97(42), 12607.
[8] Duan, X., Li, H., Kuang, D., Chen, P., Zhang, K., & Li, Y., et al. (2023). Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study. Hepatology International, 17(4), 915-926.
[9] Lv, R., Tian, Y., Yu, Z., & Liu, C. (2022). Clinical efficacy of computed tomography-guided microwave ablation sequential transcatheter arterial chemoembolization under edge calculation for primary liver cancer over 5cm in diameter. The Journal of Supercomputing, 78(9), 11298-11317.
[10] Li, K. Y., Zhang, S. M., Shi, C. X., Tang, K. L., & Huang, J. Z.. (2020). Effect of prophylactic transcatheter arterial chemoembolization on hepatocellular carcinoma with microvascular invasion after r0 resection. A case-control study. Sao Paulo Medical Journal, 138(1), 60-63.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 427
Visits: 28250

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.